830 WINTER STREET, WALTHAM, MA
Announces $55 Million Private Placement Financing
Reports First Quarter 2026 Financial Results and Provides Corporate Update
Annual Report to Security Holders
Q32 Bio Inc. Enters Controlled Equity Offering Sales Agreement for $14.2M
Financial Results, Press Release
Announces $10.5 Million Registered Direct Offering
Mark Iwicki Withdraws Resignation from Q32 Bio Board of Directors
Sells Complement Inhibitor ADX-097
Q1
FY 2025
Q3
Q2
FY 2024
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Submission Upload
Correspondence
Post-Effective Amendment to Registration Statement